endogenous glp 1 GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes GLP-1 and the kidney: from
Description
When compared against the average risk score for a diabetic member, diabetic members not taking GLP-1s are riskier than average, while those taking GLP-1s were less risky than averageand, by a wider margin
These conditions include type 2 diabetes mellitus (T2DM), cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH), among others [2]
To see if Found might be right for you, take the quiz today
theyre about confidence, comfort, and wellbeing, says Dr Lakhani
Tirzepatide targets both GLP-1 and GIP receptors (dual action)
